CureVac’s Covid-19 vaccine efficacy flags in face of new viral variants

A Covid-19 vaccine candidate based on messenger RNA technology from CureVac is showing 47% efficacy according to an interim analysis of a pivotal study. The German company blames the poor showing to new viral variants circulating in the study population.